Search Results for: TG Therapeutics Announces Orphan Drug
Articles
January 27, 2017
TG Therapeutics Announces Orphan Drug Designation January 27, 2017
TG Therapeutics, Inc. recently announced that the US FDA has granted orphan drug designation covering the combination of TG-1101 (ublituximab),...
November 7, 2023
Qualigen Therapeutics Announces First Patient Dosed in Phase 1a Clinical Trial for Treatment of Advanced or Metastatic Solid Tumors November 7, 2023
Qualigen Therapeutics, Inc. recently announced the first patient in the Phase 1a clinical trial has been dosed with QN-302, a...
October 26, 2023
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy October 26, 2023
Tenaya Therapeutics, Inc. recently announced the US FDA has provided clearance of the company’s Investigational New Drug (IND) application to...
July 10, 2023
Tonix Pharmaceuticals Announces Initiation of Enrollment in MGH Phase 2 POWER Study of Intranasal Potentiated Oxytocin for the Treatment of Pediatric Obesity July 10, 2023
Tonix Pharmaceuticals Holding Corp. recently announced the first participant was enrolled in the Phase 2 POWER study of TNX-1900 (intranasal...
June 6, 2023
European Patent Office to Grant ZyVersa Therapeutics’ Patent Application for Cholesterol Transport Mediator for Use in Patients With Diabetic Nephropathy/Diabetic Kidney Disease June 6, 2023
ZyVersa Therapeutics, Inc. recently announces the European Patent Office has issued a “Notice of Intention to Grant” ZyVersa’s patent application...
June 6, 2023
Anavex Life Sciences Announces Completion of Phase 2/3 Rett Syndrome Clinical Trial June 6, 2023
Anavex Life Sciences Corp. recently announced the completion of dosing of all participants of the placebo-controlled EXCELLENCE Phase 2/3 study...
May 23, 2023
AnaMar Announces Positive Phase 1 Data for its Phase 2 Ready Compound for Treating Fibrosis May 23, 2023
AnaMar, a clinical-stage biotech company developing a first-in-class, peripheral 5-HT2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine, recently announced...
February 14, 2023
BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer February 14, 2023
BioXcel Therapeutics, Inc. recently announced full data from its Phase 2a trial of BXCL701, the company’s investigational, oral innate immune activator, in combination with….
January 11, 2023
BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer January 11, 2023
BioXcel Therapeutics, Inc. recently announced promising top-line data from its Phase 2 trial of BXCL701, the company's investigational, oral innate...
December 6, 2022
Enzyvant Announces Merger With Altavant December 6, 2022
Combined company has full range of capabilities required to advance bold science for rare diseases in immunology and cardiopulmonology….
April 18, 2022
Revive Therapeutics Announces Publication of Research Data With Bucillamine in COVID-19 April 18, 2022
Revive Therapeutics Ltd. recently announced the publication of a scientific article evaluating the impact of medication, including Bucillamine, on antibody...
April 4, 2022
CymaBay Therapeutics Announces Results From 52-Week, Open-Label, Phase 2 Study April 4, 2022
CymaBay Therapeutics, Inc. recently announced that results from the Phase 2, 52-week study of seladelpar in patients with primary biliary...
January 31, 2022
Aravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma January 31, 2022
Aravive, Inc. recently announced it has dosed the first patient in the Phase 2 portion of the Phase 1b/2 study of batiraxcept for the treatment of clear cell renal cell carcinoma (ccRCC)…..
June 29, 2021
Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study June 29, 2021
Crinetics Pharmaceuticals, Inc. recently announced the randomization of the first acromegaly patient in its Phase 3 clinical trial of paltusotine, PATHFNDR-1. This trial will be one of two planned Phase 3 studies assessing….
March 12, 2020
Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 Study March 12, 2020
Retrophin, Inc. recently announced that the first 190 patients have been enrolled in the pivotal Phase 3 DUPLEX Study evaluating...
September 18, 2019
Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 Trial September 18, 2019
Ovid Therapeutics Inc. recently announced the first patient has been randomized in the company’s single, pivotal Phase 3 NEPTUNE clinical...
August 7, 2019
Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study August 7, 2019
Oncternal Therapeutics, Inc. recently announced it has opened for enrollment its randomized Phase 2 study of cirmtuzumab, a ROR1-targeted monoclonal...
February 21, 2019
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial February 21, 2019
ADC Therapeutics recently announced the first patient has been dosed in a Phase I clinical trial evaluating the safety, tolerability,...
June 6, 2018
MimiVax Announces Positive Interim Results from Phase II Trial of SurVaxM June 6, 2018
MimiVax LLC recently announced positive interim results from a multicenter Phase II study of SurVaxM in patients with newly diagnosed glioblastoma (nGBM).
February 7, 2017
Gemphire Announces Interim LDL-C Lowering Data From Clinical Trial February 7, 2017
Gemphire Therapeutics Inc. recently announced interim data on the LDL-C primary endpoint from the ongoing open label COBALT-1 trial. COBALT-1 is...
